Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy

morningstar.com·Jun 10, 2026 · 1 mese fa

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

biopharmadive.com·Jun 11, 2026 · 1 mese fa

Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy

biopharmadive.com·Jun 10, 2026 · 1 mese fa

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

biopharmadive.com·Jun 11, 2026 · 1 mese fa

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

statnews.com·Jun 16, 2026 · 1 mese fa

ARCH-launched Neumora stops depression program

biopharmadive.com·Jun 11, 2026 · 1 mese fa

Novartis RNA drug acquired in $12B Avidity deal notches a trial win